From Newsletters 8 & 9, May/June, 1996
Now to the technical:
"The initial testing of the relationships of ORMES with abnormal cells (cancer)
has been significantly successful (see last newsletter & enclosed) so that the
following laboratories are now also participating at their own expense.
1. Roswell Park Cancer Institute -
Conducting cell culture experiments with prostate and mammary cell lines. They
have confirmed inhibition of cancer cells and also a reduction in the thymidine
incorporation. Studies will be conducted on mRNA and then on mice SCID
experiments.
2. National Cancer Institute -
Testing ORMES on 609 cancer cell lines derived from the following types of
cancer: Colon, Central Nervous System, Leukemia, Lung, Mammary, Renal, Melanoma,
Ovarian and Prostate. The material is working in initial tests.
3. University of Illinois at Chicago -
Conducting cell culture cytotoxicity tests and mechanism - basic biochemical
tests.
4. Rutgers University -
Testing to see if ORMES helps to protect lymphocytes from acute infection from
HIV.
5. Merck and Co. -
Testing ORMES in biochemical screening for anti-cancer activities.
6. Biotechnology Institute of Oslo - (July)
Evaluating the effects of ORMES on mammary and prostate cell lines - growth and
gene expression.
7. Wayne State University -
Will evaluate ORMES in cytotoxicity based anti-cancer activities. Biochemical
assays for topoisomerase I and II inhibitors for the DNA breakage.
8. University of Wisconsin -
Scientists in the McCandlo Cancer Institute will use cell culture and/or
biochemical systems that would be useful in evaluating properties of ORMES."
From Newsletters 12 & 13 September/October, 1996 Now to RESEARCH:
"The National Institute of Health has performed cancer cell testing. Six kinds
of tests were performed on leukemia with no direct intereaction with rhodium.
Nine types of non-small cell lung cancer were tested with direct retardation of
only one type of cell by the rhodium. That was NCl-H23. There were seven
varieties of colon cancer tested with no intereaction with the rhodium. There
were six varieties of CNS cancer with no direct intereaction."
"There were eight varieties of Irialanoma with one variety referred to as the
LOX IMVI, showing a dramatic reduction of growth in the presence of rhodium. The
LOX INVI cancer cells are a melanoma form of cancer."
"There were six varieties of ovarian cancer, six varieties of renal cancer, two
varieties of prostate cancer, eight varieties of breast cancer, none of which
showed any direct intereaction with the rhodium. There was MD MID tests
performed on Delta and also on the Range showing dramatic reduction in cancer
activity."
"Members should be clear that this was not a study on human patients. It did not
measure any reaction with the thymus or other organs in the body. The tests did
not measure increases in white blood cells, T-cells, etc. it was simply a test
of the direct intereaction of one ORME (rhodium) in a cell culture."
"Additional studies were conducted in New York on PC3 independent prostate
cancer cells. At two, four and ten micrograms per milliliter the rhodium ORME
promoted DNA synthesis (measured by the thymidine incorporation), stimulated
cell growth and cell looked better than usual. Thus rhodium ORME is not toxic,
but in fact seems to make the cancer cells more vigorous and robust and clearly
does not retard PC3 cancer cells."
"Similar results occurred with mink lung epithelial cells. Incorporation of
tritiated thymidine increased from 7000 cpm to 20,000 cpm."
"In PC3 cells, rhodium ORME caused cytokine, mRNA and peptide levels to fall.
This correlates with the increased growth rates in these cells, since this
cytokine is known to inhibit cell growth. It also is known to increase in
inflammatory conditions, therefore it is possible that the decrease in the
cytokine caused by the rhodium ORME could reduce inflammation."
"At the University of Illinois, the rhodium ORME was tested in cytotoxicity
tests using eight different cell lines. None showed toxicity at levels as high
as twenty micrograms per milliliter. This shows that rhodium ORME is not toxic.
Clearly Rhodium ORME does not act on cancer cells by killing them, but many
other mechanisms which are not considered normal in cancer research are now
being investigated."
In Summary:
"Rhodium ORME is clearly not toxic, even at very high concentration. Thus its
anti-cancer action can not be via a cancer cell-killing mechanism."
"Its effects on growth of cancer cells is cell type specific. It inhibits growth
of liver cancer cell lines and the prostate line H23, but not the growth of
other cell types. It actually stimulates the growth of PC3 cells and mink lung
epithelial cells."
"It inhibits the production of cytokine in PC3 cell and mink lung epithelial
cells, which suggests the rhodium ORME may have anti-inflammatory activity."
We heartily recommend the book, "In Pursuit of Gold - Alchemy in Theory and
Practice" by Lapidus or Stephen Skinner. It is excellent and it explains most
everything and will fill in most of the blanks that you might have. You can find
a complete copy of the book below:
http://zz.com/WhiteGoldWeb/FTP/PURSUIT1.TXT
http://zz.com/WhiteGoldWeb/FTP/PURSUIT2.TXT
http://zz.com/WhiteGoldWeb/FTP/PURSUIT3.TXT
http://zz.com/WhiteGoldWeb/FTP/PURSUIT4.TXT
http://zz.com/WhiteGoldWeb/FTP/PURSUIT5.TXT
http://zz.com/WhiteGoldWeb/FTP/PURSUIT6.TXT
http://zz.com/WhiteGoldWeb/FTP/PURSUIT7.TXT
|
